News from hoth therapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

08:01 ET Hoth Therapeutics Provides Update on Novel Peptide COVID-19 Therapeutic HT-002 Preclinical Studies

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused clinical stage biopharmaceutical company, today provided an update on preclinical study on...

Mar 01, 2021, 15:02 ET Hoth Therapeutics Completes Site Recruitment for Cohort 1 of First in Human Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, is pleased to announce it has completed recruitment of Cohort 1 for its upcoming ...

Feb 26, 2021, 11:05 ET Hoth Therapeutics Expands License Agreement to Include Innovative Cancer and Anaphylactic Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has expanded its licensing agreement from North Carolina...

Feb 25, 2021, 09:55 ET Hoth Therapeutics Retains RedChip to Increase Investor Awareness

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it retained RedChip Companies, Inc. ("RedChip") to lead its...

Feb 24, 2021, 10:20 ET Hoth Therapeutics Expands Intellectual Property Portfolio with Novel Alzheimer's Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced it has filed a provisional patent application with the United...

Feb 23, 2021, 08:02 ET Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Proposed Development of HT-001 For Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today the successful completion of a pre-IND meeting with the...

Feb 18, 2021, 08:01 ET Hoth Therapeutics' HT-003 Shows Anti-inflammatory Benefits, Hoth to Expand Drug Development to Include Treatment of Inflammatory Bowel Diseases (IBDs)

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it intends to expand the development of the HT-003 active...

Feb 17, 2021, 08:00 ET Hoth Therapeutics to Present at the Diamond Equity Research Emerging Growth Invitational 2021 Virtual Conference

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it will be presenting at the upcoming the Diamond Equity...

Feb 10, 2021, 13:30 ET Hoth Therapeutics Scientific Advisory Board Member, Michael Peters, Ph.D., Publishes Whitepaper Regarding COVID-19 SARS-CoV-2 in bioRxiv

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Scientific Advisory Board member, Michael Peter, Ph.D.,...

Feb 08, 2021, 14:52 ET Hoth Therapeutics Partners with Camargo Pharmaceutical Services for the HT-001 IND, a Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed an agreement with Camargo Pharmaceutical...

Feb 02, 2021, 08:45 ET Hoth Therapeutics Provides Operational Update on Novel Therapeutic Pipeline

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company today is providing shareholders with an update on its pipeline of novel...

Jan 28, 2021, 08:02 ET Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research

Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration...

Jan 27, 2021, 08:31 ET Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board

Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("Hoth" or the "Company"), a biopharmaceutical company, today announced the addition of Mario Lacouture, M.D. ...

Jan 20, 2021, 08:38 ET Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of...

Jan 13, 2021, 08:01 ET FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001...

Jan 11, 2021, 08:02 ET Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate...

Jan 05, 2021, 09:00 ET Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase...

Jan 04, 2021, 08:01 ET Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a Non-Exclusive Commercial Evaluation...

Dec 31, 2020, 08:01 ET Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP...

Dec 23, 2020, 09:55 ET Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to...

Dec 21, 2020, 08:30 ET Endocannabinoid Pathway Targeted Drug Demonstrates Proof-of-Concept Efficacy in a Cutaneous Lupus Erythematosus Mouse Model

Hoth (NASDAQ: HOTH) has a partnership agreement with Zylö Therapeutics Inc.,to co-develop a new topical treatment for patients with Cutaneous Lupus...

Dec 10, 2020, 10:11 ET Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC)...

Nov 03, 2020, 09:25 ET Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced positive, statistically significant proof-of-concept preclinical ...

Nov 02, 2020, 10:16 ET Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced key upcoming milestones towards the commercial development of...

Oct 20, 2020, 10:30 ET Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the...